0323, 2021

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials

Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners Chicago, March 23, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, today announced $35 million in Series C Preferred Stock funding led by Paragon Biosciences. [...]

0310, 2021

CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)

Cell Therapy Platform Seeks to Restore Vision for People with RP Chicago, March 10, 2021— CiRC Biosciences, Inc., a privately held cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for chemically induced photoreceptor-like cells (CiPCs) for the treatment of retinitis pigmentosa (RP). With an initial focus [...]

0223, 2021

Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer

Chicago, February 23, 2021—With continued growth in its portfolio of life science companies, Paragon Biosciences announced the appointment of Jordan Dubow, M.D., as chief medical officer. Dr. Dubow is responsible for identifying and evaluating innovation opportunities utilizing his clinical and regulatory expertise and providing guidance to Paragon’s seven portfolio companies. Headquartered in Chicago, Paragon [...]

022, 2021

Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform

Its vision restoration technology featured in Nature and New England Journal of Medicine; CiRC is Paragon’s 7 th portfolio company, with more in development Chicago, February 2, 2021 – Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence, today announced [...]

1215, 2020

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering

Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient has been dosed in its Phase 2 clinical trial evaluating ecopipam, the company’s investigational medicine, for the treatment of childhood-onset fluency disorder, or “stuttering.” [...]

099, 2020

Jon DeVries Named Qlarity Imaging Chief Executive Officer

Chicago, September 9, 2020 – Life science innovator Paragon Biosciences announced the appointment of Jon T. DeVries as the new chief executive officer of its portfolio company, Qlarity Imaging, a leading artificial intelligence (AI) diagnostics company. A proven leader with in-depth expertise in developing and commercializing medical imaging and AI solutions, Mr. DeVries will be responsible for [...]

Go to Top